Boston Therapeutics (OTCMKTS:BTHE) and ANCHIANO THERAP/S (NASDAQ:ANCN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
This table compares Boston Therapeutics and ANCHIANO THERAP/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Boston Therapeutics has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Comparatively, ANCHIANO THERAP/S has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Institutional & Insider Ownership
12.7% of ANCHIANO THERAP/S shares are owned by institutional investors. 15.7% of Boston Therapeutics shares are owned by insiders. Comparatively, 6.9% of ANCHIANO THERAP/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Boston Therapeutics and ANCHIANO THERAP/S’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Boston Therapeutics||$20,000.00||64.46||-$3.69 million||N/A||N/A|
|ANCHIANO THERAP/S||N/A||N/A||-$27.12 million||($3.46)||-0.31|
Boston Therapeutics has higher revenue and earnings than ANCHIANO THERAP/S.
This is a summary of recent recommendations and price targets for Boston Therapeutics and ANCHIANO THERAP/S, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ANCHIANO THERAP/S has a consensus price target of $16.00, suggesting a potential upside of 1,395.33%. Given ANCHIANO THERAP/S’s higher possible upside, analysts clearly believe ANCHIANO THERAP/S is more favorable than Boston Therapeutics.
ANCHIANO THERAP/S beats Boston Therapeutics on 5 of the 9 factors compared between the two stocks.
About Boston Therapeutics
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.
About ANCHIANO THERAP/S
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Boston Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.